Association of Bacillus anthracis capsule with lethal toxin during experimental infection.
about
Microbial synthesis of poly-γ-glutamic acid: current progress, challenges, and future perspectivesAnthrax prophylaxis: recent advances and future directionsThe Protective Antigen Component of Anthrax Toxin Forms Functional Octameric ComplexesAnthrax toxin protective antigen integrates poly- -D-glutamate and pH signals to sense the optimal environment for channel formationAnthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsuleQuantitative anti-PA IgG ELISA; assessment and comparability with the anthrax toxin neutralization assay in goats.The poly-γ-D-glutamic acid capsule of Bacillus anthracis enhances lethal toxin activity.High-sensitivity MALDI-TOF MS quantification of anthrax lethal toxin for diagnostics and evaluation of medical countermeasuresThe Poly-γ-d-Glutamic Acid Capsule Surrogate of the Bacillus anthracis Capsule Is a Novel Toll-Like Receptor 2 Agonist.Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthraxAnthrax toxin-induced rupture of artificial lipid bilayer membranes.Anthrax lethal toxin co-complexes are stabilized by contacts between adjacent lethal factors.New insights into the biological effects of anthrax toxins: linking cellular to organismal responsesAnthrax vaccines: present status and future prospects.
P2860
Q26745732-95ABC826-20CD-4DEA-AC1E-DD0E5633C40FQ26781366-E3233947-E177-40D7-91F8-0CD5862CE991Q27656672-ECBDEFEA-FA6A-4E9D-B5E3-B82454CC90E6Q27674720-69AAF9F4-CF01-490A-8D9B-E804BEAFBCEBQ33747662-06EF34C5-BBD7-4C89-AE9C-2BF0FA8448F8Q33942561-59A79F06-C3CE-4CD1-AE27-EE984F53BBF6Q34490786-694C0405-ACD6-4B04-B9A7-C39AAD0604D3Q35077052-4113D8FE-CDF1-4398-ACCE-30960CA58996Q35191941-B27F644B-B242-417D-8470-D266CD994AADQ35205013-244532D8-C666-4741-8824-F2A243C0ABE3Q36053487-A3EB98A0-D2AA-46B8-A3A7-F004DC18E766Q36155940-E4744C51-2A33-4B36-9AA3-C93043C8D04FQ37117091-6390D57B-CF91-4E97-941D-C7F363EAD1E9Q37285225-1A349F4A-C808-44A8-BFD5-0E7285FCC156Q37935265-CC928F04-BF03-4C17-B3A3-E680ADED7BBDQ38132268-46A8EF5A-88E6-46A2-9FB7-16273C158E2E
P2860
Association of Bacillus anthracis capsule with lethal toxin during experimental infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Association of Bacillus anthra ...... during experimental infection.
@en
Association of Bacillus anthra ...... during experimental infection.
@nl
type
label
Association of Bacillus anthra ...... during experimental infection.
@en
Association of Bacillus anthra ...... during experimental infection.
@nl
prefLabel
Association of Bacillus anthra ...... during experimental infection.
@en
Association of Bacillus anthra ...... during experimental infection.
@nl
P2093
P2860
P356
P1476
Association of Bacillus anthra ...... during experimental infection.
@en
P2093
A M Friedlander
E K Leffel
J W Ezzell
T G Abshire
P2860
P304
P356
10.1128/IAI.00764-08
P407
P577
2008-12-08T00:00:00Z